<DOC>
	<DOCNO>NCT01852812</DOCNO>
	<brief_summary>This study evaluate safety pharmacokinetics montelukast ( MK-0476 ) treatment Japanese pediatric participant perennial allergic rhinitis ( PAR ) . The primary hypothesis study montelukast oral granule ( OG ) chewable tablet ( CT ) provide appropriate exposure montelukast Japanese pediatric participant PAR .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics Montelukast ( MK-0476 ) Treatment Japanese Pediatric Participants With Perennial Allergic Rhinitis ( MK-0476-520 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Weight â‰¥8 kg Diagnosis PAR symptom PAR Visit 1 Past present medical history asthma Diagosis acute rhinitis , simple rhinitis , rhinitis congestive , rhinitis atrophic , sinusitis purulent nasal discharge , rhinitis medicamentosa nonallergic rhinitis ( e.g . vasomotor rhinitis , eosinophilic rhinitis ) Started hyposensitization therapy nonspecific immunotherapy within 6 month prior Visit 1 Medical history inferior concha mucosal resection , submucous resection inferior turbinate surgery aim reduction and/or modulation nasal mucosa ( include electrocoagulation , cryoextraction application trichloroacetic acid ) Clinically significant , active disease cardiovascular hematologic system uncontrolled hypertension ( 1 5 year old : &gt; 120/70 mmHg ; 6 9 year old : &gt; 130/80 mmHg ; 10 15 year old : &gt; 140/85 mmHg ) Medical history stunt growth Serious drug allergy Treated clinical study drug within 3 month prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>